centurytx.com (IPSC): Net earnings per share growth forecast for next year

Century Therapeutics is scaling allogeneic iPSC therapies with the support of pharmaceutical behemoths. High barriers to entry are ensured by gene editing patents and the complexity of biomanufacturing. Next year's EPS outlook reflects market expectations, where the indicator level stands at 15.70. Price stability is guaranteed by competent management with deep R&D experience and transparency in investment processes.

Century Therapeutics (IPSC): Net earnings per share growth forecast for next year from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for Century Tx (IPSC)

- share price and consensus valuation forecast:

Stock Price Century Tx|IPSC - Average Forecast Price

- stock exchange capitalization data:

Market Value Century Tx|IPSC - Total Company Value

- company book value details:

Net Assets per Single Share Century Therapeutics|IPSC - Company Book Value|Market Cap to Net Assets Ratio centurytx.com|IPSC - Aggregate Asset Value

- debt and solvency information:

- net income and valuation ratios data:

IPSC - Final Profit|Future Profit Century Therapeutics|IPSC - Market Price to Net Income Ratio|Forward P/E Multiple centurytx.com|IPSC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Century Therapeutics|IPSC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Century Therapeutics|IPSC - Earnings per share for the trailing year|Quarterly EPS earnings growth centurytx.com|IPSC - Earnings growth in current year|Net earnings per share growth forecast for next year Century Therapeutics

- company sales and revenue statistics:

IPSC - Company Annual Revenue|Company Future Sales Volume Century Tx|IPSC - Price to Sales|Forward P/S Multiple Century Therapeutics Inc|IPSC - Revenue Growth YoY (Last 12 Months)

Fundamental company analysis:IPSC, Century Therapeutics Inc

Finished products of Century Therapeutics, Inc.

Profit dynamics for Century Therapeutics (IPSC) depend directly on the efficiency of molecule screening robotization and the automation of clinical data processing. Analyzing the projected EPS growth rate for next year, the investor observes analyst consensus earnings expectations, calculated based on daily price action to assess trend sustainability. The stable range of this metric confirms the company's fundamental value, although buying at the peak of expectations increases the risk of a correction.

Competing companies